Neurocrine Biosciences Details $2.9B Soleno Buyout, Touts Vykat XR as Potential Blockbuster [Yahoo! Finance]
Neurocrine Biosciences, Inc. (NBIX)
Last neurocrine biosciences, inc. earnings: 2/4 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
neurocrine.com/about-us/webcasts-presentations
Company Research
Source: Yahoo! Finance
Neurocrine Biosciences (NASDAQ:NBIX) detailed its planned acquisition of Soleno Therapeutics on a conference call Monday, outlining the deal terms, the strategic rationale, and expectations for expanding the reach of Soleno's newly launched rare disease medicine Vykat XR. Deal terms and financing Chief Executive Officer Kyle Gano said Neurocrine has entered into a definitive agreement to acquire Soleno via a cash tender offer for all outstanding shares at $53 per share , implying an enterprise value of approximately $2.9 billion . Gano said the transaction is not subject to a financing condition and will be funded with cash on hand, with Neurocrine planning to “optimize our capital structure by taking on a modest level of pre-payable debt.” ? 3 Utility Stocks With Strong Dividends and Room to Run Higher Bristol Myers Squibb's big buys: $18.1 billion in 2 biotech deals Chief Financial Officer Matt Abernethy added that the acquisition is expected to be accretive, saying it wi
Show less
Read more
Impact Snapshot
Event Time:
NBIX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NBIX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NBIX alerts
High impacting Neurocrine Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
NBIX
News
- Stock Market Today, April 6: Soleno Therapeutics Climbs After $2.9 Billion All-Cash Buyout Agreement [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- Why Soleno Therapeutics Stock Rocketed Higher on Monday [Yahoo! Finance]Yahoo! Finance
- Neurocrine Biosciences (NBIX) had its "buy" rating reaffirmed by Needham & Company LLC. They now have a $185.00 price target on the stock.MarketBeat
- Neurocrine Biosciences, Inc. (NBIX) M&A Call Transcript [Seeking Alpha]Seeking Alpha
- Neurocrine to acquire Prader-Will drug in $2.9B Soleno buyout [Yahoo! Finance]Yahoo! Finance
NBIX
Earnings
- 2/11/26 - Beat
NBIX
Sec Filings
- 4/6/26 - Form 8-K
- 3/27/26 - Form SCHEDULE
- 3/17/26 - Form 3
- NBIX's page on the SEC website